**Vasogen
                Inc.**
              
              **Contact:**
              Glenn
                Neumann, Investor Relations
              2505
                Meadowvale Blvd
              Mississauga,
                ON, Canada L5N 5S2
              tel:
                (905) 817-2004 fax: (905) 569-9231
              www.vasogen.com
                / investor@vasogen.com







***FOR
      IMMEDIATE RELEASE***










**Vasogen
      to Conduct Quarterly Conference Call**








**Mississauga,
      Ontario (April 11, 2006) -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS),** a
      leader
      in the research and commercial development of technologies targeting the chronic
      inflammation underlying cardiovascular and neurological disease, **** will
      release its quarterly results after the close of the North American financial
      markets on Monday, April 17, 2006. A live webcast presentation and conference
      call will be conducted on Tuesday, April 18, 2006 at 8:30 a.m. Eastern Time,
      during which management will provide a Company update and discuss first quarter
      results.





To
      participate via live webcast and view the slide presentation, please go to www.vasogen.com .





To
      participate by telephone, please connect 10 minutes prior to the call to one
      of
      the following:




Direct
                Dial
            416-695-6622Toll-free
            1-800-769-8320





Telephone
      participants can also log onto www.vasogen.com to
      follow the slide presentation and will have the opportunity to ask questions.




A
      re-broadcast of the conference call will be available at www.vasogen.com and may
      also be accessed by:





Direct
                Dial
            416-641-2126Toll-free
            1-800-293-5765
              Pin
                code: 8019













**-more-**














**...page
      2, April 11, 2006**








**About
      Vasogen:**


Vasogen
      is focused on the research and commercial development of technologies targeting
      the chronic inflammation underlying cardiovascular and neurological disease.
      The
      Company’s lead product, the CelacadeTM technology, is currently in the final
      stages of the 2,400-patient international pivotal phase III ACCLAIM trial in
      patients with advanced chronic heart failure. The 176-center ACCLAIM study
      is
      designed to further investigate the use of the Celacade technology to reduce
      the
      risk of death and hospitalization in heart failure patients and to support
      regulatory approval in North America and commercialization in North America
      and
      Europe. Vasogen is also developing a new class of drugs for the treatment of
      neuro-inflammatory disorders. VP025, which has completed phase I clinical
      development, is the lead product candidate from this new class of
      drugs.





*Certain
      statements contained in this press release and upcoming conference call
      constitute “forward-looking statements” within the meaning of the United States
      Private Securities Litigation Reform Act of 1995. These statements include,
      without limitation, statements concerning our strategy, future operations,
      future financial position, future revenues, projected costs, prospects, plans
      and objectives of management. In some cases, you can identify forward-looking
      statements by terminology such as “may”, “will”, “should”, “expects”, “plans”,
“anticipates”, “believes”, “estimated”, “predicts”, “potential”, “continue”,
“intends”, “could”, or the negative of such terms or other comparable
      terminology. You should not place undue reliance on our forward-looking
      statements which are subject to a multitude of risks and uncertainties that
      could cause actual results, future circumstances or events to differ materially
      from those projected in the forward-looking statements. These risks include,
      but
      are not limited to, those associated with the success of our research and
      development programs, the adequacy, timing and results of our clinical trials,
      the need for additional capital and the effect of capital market conditions
      and
      other factors on capital availability, the potential dilutive effects of any
      financing, the regulatory approval process, competition, securing and
      maintaining corporate alliances, market acceptance of our products, the
      availability of government and insurance reimbursements for our products, the
      strength of intellectual property, reliance on subcontractors and key personnel,
      losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks
      detailed from time to time in our public disclosure documents or other filings
      with the Canadian and U.S. securities commissions or other securities regulatory
      bodies. The forward-looking statements are made as of the date hereof, and
      we
      disclaim any intention and have no obligation or responsibility, except as
      required by law, to update or revise any forward-looking statements, whether
      as
      a result of new information, future events or otherwise.*